Jasper Therapeutics jumps on update for lead product candidate

Jasper Therapeutics

10/01/2023 13:44

** Shares of Jasper Therapeutics Inc  JSPR.O  rise ~21% to
$1.92 premarket  
    ** Biotech co says it will focus on development of its lead
product candidate, briquilimab, in chronic diseases and stem
cell transplant for rare diseases as part of an overall
portfolio prioritization
    ** Says it does not have near-term plans to initiate a
late-stage trial for briquilimab in blood cancers known as acute
myeloid leukemia (AMD) and myelodysplastic syndromes (MDS)
    ** Will continue to work in the meantime with U.S. FDA,
transplant community and potential partners to ensure
briquilimab remains ready for late-stage study in AML/MDS stem
cell transplant - Jasper
    ** Also adds that co has prioritized rapidly starting a
clinical study in severe chronic urticaria, a type of skin
disease 
    ** JSPR shares lost ~94% of their value in 2022
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))